Page 996 - Read Online

Machado. Hepatoma Res 2020;6:84 I http://dx.doi.org/10.20517/2394-5079.2020.90 Page 17 of 18

non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells. Metabolism
2014;63:1352-62.
114. BasuRay S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid
droplets by evading ubiquitylation. Hepatology 2017;66:1111-24.
115. Nishioji K, Mochizuki N, Kobayashi M, et al. The impact of PNPLA3 rs738409 genetic polymorphism and weight gain >/=10 kg after
age 20 on non-alcoholic fatty liver disease in non-obese japanese individuals. PLoS One 2015;10:e0140427.
116. Honda Y, Yoneda M, Kessoku T, et al. Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental
factors. Hepatol Res 2016;46:1011-8.
117. Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.
Hepatology 2017;65:54-64.
118. Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and
association with visceral obesity. Clin Gastroenterol Hepatol 2017;15:1604-11.e1.
119. Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol 2019;70:531-44.
120. Fan Y, Lu H, Guo Y, et al. Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology
2016;150:1208-18.
121. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to
nonalcoholic fatty liver disease. Nat Genet 2014;46:352-6.
122. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver
disease. Nat Commun 2014;5:4309.
123. Goffredo M, Caprio S, Feldstein AE, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease:
a multiethnic study. Hepatology 2016;63:117-25.
124. Chen X, Zhou P, De L, Li B, Su S. The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver
disease: a meta-analysis of 24,147 subjects. Mol Genet Genomic Med 2019;7:e824.
125. Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis
from cardiovascular disease. Hepatology 2015;61:506-14.
126. Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology
2020;71:1213-27.
127. Adams LA, Marsh JA, Ayonrinde OT, et al. Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in
females independent of adiposity. J Gastroenterol Hepatol 2012;27:1520-7.
128. Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD
incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013;62:1109-20.
129. Bale G, Vishnubhotla RV, Mitnala S, et al. Whole-exome sequencing identifies a variant in phosphatidylethanolamine N-methyltransferase
gene to be associated with lean-nonalcoholic fatty liver disease. J Clin Exp Hepatol 2019;9:561-8.
130. Dong H, Wang J, Li C, et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers
the susceptibility to NASH in Japanese population. J Hepatol 2007;46:915-20.
131. Song J, da Costa KA, Fischer LM, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD).
FASEB J 2005;19:1266-71.
132. Nakatsuka A, Matsuyama M, Yamaguchi S, et al. Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-
alcoholic steatohepatitis. Sci Rep 2016;6:21721.
133. Yun Y, Kim HN, Lee EJ, et al. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean
subjects. PLoS One 2019;14:e0213692.
134. Machado MV, Cortez-Pinto H. Diet, microbiota, obesity, and NAFLD: a dangerous quartet. Int J Mol Sci 2016;17:481.
135. Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in
nonalcoholic fatty liver disease. Hepatology 2019;69:107-20.
136. Elshaghabee FMF, Bockelmann W, Meske D, et al. Ethanol production by selected intestinal microorganisms and lactic acid bacteria
growing under different nutritional conditions. Front Microbiol 2016;7:47.
137. Elshaghabee FMF, Ghadimi D, Habermann D, et al. Effect of oral administration of weissella confusa on fecal and plasma ethanol
concentrations, lipids and glucose metabolism in wistar rats fed high fructose and fat diet. Hepat Med 2020;12:93-106.
138. Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver
disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2019;9:e017995.
139. Kwak JH, Jun DW, Lee SM, et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: a cross-
sectional study. Clin Nutr 2018;37:1550-7.
140. Assy N, Nasser G, Kamayse I, et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J
Gastroenterol 2008;22:811-6.
141. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic
steatohepatitis. Hepatology 2003;37:909-16.
142. Bardella MT, Valenti L, Pagliari C, et al. Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis
2004;36:333-6.
143. Emami MH, Hashemi M, Kouhestani S, Taheri H, Karimi S. Should we look for celiac disease among all patients with liver function test
abnormalities? Int J Prev Med 2012;3:167-72.